These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 26209972)
1. Long-term outcomes of fertility-sparing treatment of atypical polypoid adenomyoma with medroxyprogesterone acetate. Nomura H; Sugiyama Y; Tanigawa T; Matoda M; Kanao H; Kondo E; Takeshima N Arch Gynecol Obstet; 2016 Jan; 293(1):177-181. PubMed ID: 26209972 [TBL] [Abstract][Full Text] [Related]
2. Maintenance hormonal therapy after treatment with medroxyprogesterone acetate for patients with atypical polypoid adenomyoma. Nomura H; Sugiyama Y; Tanigawa T; Matoda M; Okamoto S; Omatsu K; Kanao H; Kato K; Utsugi K; Takeshima N Jpn J Clin Oncol; 2018 Mar; 48(3):255-258. PubMed ID: 29351618 [TBL] [Abstract][Full Text] [Related]
3. Efficacies and pregnant outcomes of fertility-sparing treatment with medroxyprogesterone acetate for endometrioid adenocarcinoma and complex atypical hyperplasia: our experience and a review of the literature. Ohyagi-Hara C; Sawada K; Aki I; Mabuchi S; Kobayashi E; Ueda Y; Yoshino K; Fujita M; Tsutsui T; Kimura T Arch Gynecol Obstet; 2015 Jan; 291(1):151-7. PubMed ID: 25118836 [TBL] [Abstract][Full Text] [Related]
4. Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002). Park JY; Kim DY; Kim JH; Kim YM; Kim KR; Kim YT; Seong SJ; Kim TJ; Kim JW; Kim SM; Bae DS; Nam JH Eur J Cancer; 2013 Mar; 49(4):868-74. PubMed ID: 23072814 [TBL] [Abstract][Full Text] [Related]
5. Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin. Simpson AN; Feigenberg T; Clarke BA; Gien LT; Ismiil N; Laframboise S; Massey C; Ferguson SE Gynecol Oncol; 2014 May; 133(2):229-33. PubMed ID: 24561246 [TBL] [Abstract][Full Text] [Related]
6. [Atypical polypoid adenomyoma of the uterus: a clinicopathological review of 27 cases]. Bai TJ; Bao DM; Li Y; Wang Y; Cui H; Zhu HL Zhonghua Fu Chan Ke Za Zhi; 2017 Apr; 52(4):244-248. PubMed ID: 28441840 [No Abstract] [Full Text] [Related]
7. Effectiveness of high-dose progestin and long-term outcomes in young women with early-stage, well-differentiated endometrioid adenocarcinoma of uterine endometrium. Park H; Seok JM; Yoon BS; Seong SJ; Kim JY; Shim JY; Park CT Arch Gynecol Obstet; 2012 Feb; 285(2):473-8. PubMed ID: 21706284 [TBL] [Abstract][Full Text] [Related]
8. Pregnancy and oncologic outcomes after fertility-sparing management for early stage endometrioid endometrial cancer. Chae SH; Shim SH; Lee SJ; Lee JY; Kim SN; Kang SB Int J Gynecol Cancer; 2019 Jan; 29(1):77-85. PubMed ID: 30640687 [TBL] [Abstract][Full Text] [Related]
9. Update on the oncologic and obstetric outcomes of medroxyprogesterone acetate treatment for atypical endometrial hyperplasia and endometrial cancer. Tamauchi S; Nakagawa A; Yoshida K; Yoshihara M; Yokoi A; Yoshikawa N; Niimi K; Kajiyama H J Obstet Gynaecol Res; 2024 Sep; 50(9):1614-1621. PubMed ID: 39092804 [TBL] [Abstract][Full Text] [Related]
10. Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer. Mitsuhashi A; Sato Y; Kiyokawa T; Koshizaka M; Hanaoka H; Shozu M Ann Oncol; 2016 Feb; 27(2):262-6. PubMed ID: 26578736 [TBL] [Abstract][Full Text] [Related]
11. Hysteroscopic Transcervical Resection for Atypical Polypoid Adenomyoma of the Uterus: A Valid, Fertility-Preserving Option. Chiyoda T; Lin BL; Saotome K; Kiyokawa S; Nakada S J Minim Invasive Gynecol; 2018 Jan; 25(1):163-169.e1. PubMed ID: 29038039 [TBL] [Abstract][Full Text] [Related]
12. Pregnant outcomes of atypical polypoid adenomyoma treated with progestin therapy. Chen Q; Lu W; Lu B J Obstet Gynaecol Res; 2018 Feb; 44(2):323-330. PubMed ID: 29121416 [TBL] [Abstract][Full Text] [Related]
13. Factors affecting pregnancy outcomes in young women treated with fertility-preserving therapy for well-differentiated endometrial cancer or atypical endometrial hyperplasia. Inoue O; Hamatani T; Susumu N; Yamagami W; Ogawa S; Takemoto T; Hirasawa A; Banno K; Kuji N; Tanaka M; Aoki D Reprod Biol Endocrinol; 2016 Jan; 14():2. PubMed ID: 26769300 [TBL] [Abstract][Full Text] [Related]
14. Conservative treatment with progestin and pregnancy outcomes in endometrial cancer. Hahn HS; Yoon SG; Hong JS; Hong SR; Park SJ; Lim JY; Kwon YS; Lee IH; Lim KT; Lee KH; Shim JU; Mok JE; Kim TJ Int J Gynecol Cancer; 2009 Aug; 19(6):1068-73. PubMed ID: 19820370 [TBL] [Abstract][Full Text] [Related]
15. Pregnancy outcomes after fertility-sparing management in young women with early endometrial cancer. Park JY; Seong SJ; Kim TJ; Kim JW; Kim SM; Bae DS; Nam JH Obstet Gynecol; 2013 Jan; 121(1):136-42. PubMed ID: 23262938 [TBL] [Abstract][Full Text] [Related]
16. Oncologic and obstetrical outcomes after fertility-preserving retreatment in patients with recurrent atypical endometrial hyperplasia and endometrial cancer. He Y; Wang Y; Zhou R; Wang J Int J Gynecol Cancer; 2020 Dec; 30(12):1902-1907. PubMed ID: 33051245 [TBL] [Abstract][Full Text] [Related]
17. Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility? Yamagami W; Susumu N; Makabe T; Sakai K; Nomura H; Kataoka F; Hirasawa A; Banno K; Aoki D J Gynecol Oncol; 2018 Mar; 29(2):e21. PubMed ID: 29400014 [TBL] [Abstract][Full Text] [Related]
18. Coexistence of endometrioid adenocarcinoma in atypical polypoid adenomyoma. Sonoyama A; Kanda M; Ojima Y; Kizaki T; Ohara N Kobe J Med Sci; 2014 Dec; 60(3):E74-7. PubMed ID: 25612673 [TBL] [Abstract][Full Text] [Related]
19. Fertility sparing treatment in patients with endometrial cancer (FERT-ENC): a multicentric retrospective study from the Spanish Investigational Network Gynecologic Oncology Group (SPAIN-GOG). Lago V; Marina T; Laseca Modrego M; Gil-Ibañez B; Rodriguez JR; Domingo J; Minig L; Padilla-Iserte P; Arencibia Sánchez O; Sala Ferichola M; Munmanny M; Martín Salamanca B; Iacoponi S; Cabrera S; Coronado P; Utrilla-Layna J; Bataller Á; Fiol G; Corbalán S; Espinosa E; Gil-Moreno A; Domingo S; Arch Gynecol Obstet; 2022 Sep; 306(3):821-828. PubMed ID: 35122158 [TBL] [Abstract][Full Text] [Related]
20. Combined Oral Medroxyprogesterone/Levonorgestrel-Intrauterine System Treatment for Women With Grade 2 Stage IA Endometrial Cancer. Hwang JY; Kim DH; Bae HS; Kim ML; Jung YW; Yun BS; Seong SJ; Shin E; Kim MK Int J Gynecol Cancer; 2017 May; 27(4):738-742. PubMed ID: 28346240 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]